



March 8, 2011

Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16

PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the Roth 23rd Annual OC Growth Stock Conference at 11:30 a.m. Pacific time on Wednesday, March 16, 2011. The conference is being held at the Ritz Carlton in Laguna Niguel, California.

Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowhead's CEO Dr. Christopher Anzalone by contacting conference@roth.com, or Brandi Floberg at arrowres@tpg-ir.com or 212-481-2050.

The presentation will be webcast live and can be accessed by visiting the Company's website at www.arrowheadresearch.com. A replay of the presentation will be archived on the Arrowhead website for 90 days.

About Arrowhead Research Corporation

Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit <http://www.arrowheadresearch.com>.

Contacts:
Brandi Floberg

The Piacente Group, Inc.

212-481-2050
arrowres@tpg-ir.com